Article

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variant

2022-01-19

Abstract excerpt

Variants of SARS-CoV-2 have become a major public health concern due to increased transmissibility, and escape from natural immunity, vaccine protection, and monoclonal antibody therapeutics. The highly transmissible Omicron variant has up to 32 mutations within the spike protein, many more than previous variants, heightening these concerns of immune escape. There are now multiple antiviral therapeutics that have...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0df35a76-5001-5663-8d20-93dd783406bb
DOI: 10.1101/2022.01.17.476685

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variantDOI 10.1101/2022.01.17.476685Read

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.Semantic proximity Read

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)Semantic proximity Read

Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain ResistanceSemantic proximity Read

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variantsSemantic proximity Read

Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025.Semantic proximity Read

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariantsSemantic proximity Read

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity Read

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron VariantsSemantic proximity Read

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read